PubRank

Nicholas W Morrell

Author PubWeight™ 133.82‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004 5.79
2 Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009 3.75
3 Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005 3.16
4 Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002 3.08
5 Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010 3.02
6 A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011 2.89
7 An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008 2.71
8 Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013 2.64
9 Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010 2.44
10 Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006 2.30
11 Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005 2.21
12 Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 2006 1.85
13 Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002 1.85
14 Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. Circ Res 2013 1.80
15 MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res 2013 1.80
16 Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am J Respir Crit Care Med 2009 1.78
17 Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009 1.75
18 Flexibility and diversity in consultant careers. Clin Med 2002 1.71
19 Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010 1.69
20 BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006 1.69
21 Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem 2009 1.68
22 A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res 2012 1.61
23 Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2015 1.60
24 Praziquantel reverses pulmonary hypertension and vascular remodeling in murine schistosomiasis. Am J Respir Crit Care Med 2011 1.59
25 Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension. Circulation 2012 1.59
26 Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med 2009 1.58
27 Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension. Hum Mol Genet 2003 1.44
28 Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005 1.40
29 ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002 1.39
30 Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ Res 2008 1.31
31 BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 2013 1.29
32 Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol 2008 1.19
33 Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 2011 1.18
34 MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling. Cardiovasc Res 2011 1.15
35 Neutrophils from patients with heterozygous germline mutations in the von Hippel Lindau protein (pVHL) display delayed apoptosis and enhanced bacterial phagocytosis. Blood 2006 1.15
36 Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2006 1.13
37 Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest 2010 1.12
38 Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. Hum Mol Genet 2008 1.11
39 Gremlin plays a key role in the pathogenesis of pulmonary hypertension. Circulation 2012 1.11
40 Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor. Chest 2008 1.11
41 BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways. Am J Physiol Lung Cell Mol Physiol 2004 1.09
42 The renin-angiotensin system in pulmonary hypertension. Am J Respir Crit Care Med 2013 1.08
43 Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007 1.08
44 Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res 2013 1.08
45 Partial contributions of developmental hypoxia and undernutrition to prenatal alterations in somatic growth and cardiovascular structure and function. Am J Obstet Gynecol 2010 1.07
46 Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells. Mol Pharmacol 2007 1.06
47 Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2010 1.06
48 BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. Am J Physiol Lung Cell Mol Physiol 2012 1.06
49 Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem 2010 1.05
50 Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 2011 1.04
51 Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension. Circulation 2007 1.04
52 Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension. Hum Mol Genet 2008 1.04
53 An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med 2014 1.02
54 Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006 1.01
55 Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 2012 1.01
56 cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 2004 1.00
57 Right ventricular dysfunction in chronic thromboembolic obstruction of the pulmonary artery: a pressure-volume study using the conductance catheter. J Appl Physiol (1985) 2013 0.99
58 Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med 2012 0.97
59 Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ Res 2010 0.97
60 Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol Cell Biol 2013 0.96
61 Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2013 0.96
62 BMP4 induces HO-1 via a Smad-independent, p38MAPK-dependent pathway in pulmonary artery myocytes. Am J Respir Cell Mol Biol 2007 0.95
63 A practical and efficient cellular substrate for the generation of induced pluripotent stem cells from adults: blood-derived endothelial progenitor cells. Stem Cells Transl Med 2012 0.95
64 Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2013 0.95
65 The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. Hum Mol Genet 2013 0.94
66 Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension. Compr Physiol 2011 0.93
67 (18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study. Pulm Circ 2012 0.93
68 BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production. PLoS One 2012 0.93
69 Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension. Proc Am Thorac Soc 2010 0.92
70 Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension. Am J Respir Crit Care Med 2007 0.91
71 Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med 2002 0.91
72 Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2002 0.90
73 Differential effects of TGF-beta1 and BMP-4 on the hypoxic induction of cyclooxygenase-2 in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2004 0.88
74 New therapeutic agents for pulmonary vascular disease. Paediatr Respir Rev 2005 0.88
75 Transforming growth factor-β(1) represses bone morphogenetic protein-mediated Smad signaling in pulmonary artery smooth muscle cells via Smad3. Am J Respir Cell Mol Biol 2013 0.88
76 Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells. Pulm Circ 2011 0.88
77 Eotaxin-1/CC chemokine ligand 11: a novel eosinophil survival factor secreted by human pulmonary artery endothelial cells. J Immunol 2007 0.87
78 Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase. Am J Physiol Lung Cell Mol Physiol 2004 0.86
79 Occlusion pressure analysis role in partitioning of pulmonary vascular resistance in CTEPH. Eur Respir J 2012 0.86
80 The transforming growth factor-β-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease. Exp Physiol 2013 0.85
81 Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. Pulm Circ 2013 0.85
82 Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice. Am J Pathol 2013 0.85
83 Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2010 0.85
84 Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ 2013 0.84
85 Trapping of BMP receptors in distinct membrane domains inhibits their function in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2011 0.82
86 Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. Pulm Pharmacol Ther 2010 0.82
87 Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension. Pulm Circ 2012 0.82
88 TGF-beta and BMPR-II pharmacology--implications for pulmonary vascular diseases. Curr Opin Pharmacol 2009 0.81
89 A novel RASA1 mutation causing capillary malformation-arteriovenous malformation (CM-AVM) presenting during pregnancy. Am J Med Genet A 2013 0.80
90 Genetics and the molecular pathogenesis of pulmonary arterial hypertension. Curr Hypertens Rep 2013 0.79
91 Inhibition of overactive transforming growth factor-β signaling by prostacyclin analogs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2013 0.78
92 Late outgrowth endothelial progenitor cells engineered for improved survival and maintenance of function in transplant-related injury. Transpl Int 2011 0.78
93 Pulmonary Circulation : A new venue for communicating your findings, ideas and perspectives. Pulm Circ 2011 0.78
94 Assessment of a pulmonary origin for blood outgrowth endothelial cells by examination of identical twins harboring a BMPR2 mutation. Am J Respir Crit Care Med 2013 0.78
95 Primary pulmonary hypertension: molecular basis and potential for therapy. Expert Rev Mol Med 2004 0.77
96 MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. J Clin Invest 2016 0.77
97 Waiting in anticipation: the genetics of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 0.76
98 Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension. Am J Respir Crit Care Med 2014 0.76
99 Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. Thorax 2007 0.76
100 Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. Pulm Circ 2011 0.76
101 Understanding the low penetrance of bone morphogenetic protein receptor 2 gene mutations: another needle in the haystack. Circulation 2012 0.75
102 Clinical demonstration of efficiency and reversibility of hypoxic pulmonary vasoconstriction in a patient presenting with unilateral incomplete bronchial occlusion. Pulm Circ 2011 0.75
103 The world of pulmonary vascular disease. Pulm Circ 2011 0.75
104 No doctor is an island. Pulm Circ 2012 0.75
105 Screening for pulmonary arteriovenous malformations. Am J Respir Crit Care Med 2004 0.75
106 Science is an endless frontier: Encouraging translational research in pulmonary vascular disease. Pulm Circ 2012 0.75
107 [Relevant issues in the pathology and pathobiology of pulmonary hypertension]. Turk Kardiyol Dern Ars 2014 0.75
108 Our journey continues. Pulm Circ 2011 0.75
109 Readership: The heart of Pulmonary Circulation. Pulm Circ 2013 0.75
110 New frontiers in pulmonary hypertension. Expert Rev Respir Med 2011 0.75
111 Does BMPR2 mutation disrupt pulmonary vasculogenesis? Chest 2005 0.75
112 A one-year-old baby… into the Year of the Dragon. Pulm Circ 2012 0.75